Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.68 |
| ▸ | NPY2R | P49146 | 1/20 | 0.68 |
| ▸ | NPY4R | P50391 | 1/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 5/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.63 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynorphin A (1-17) SCHEMBL31331988 | 1.00 | NPY1R (0.68) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30589447 | 0.98 | CXCR4 (0.68) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30439395 | 0.94 | OPRD1 (0.67) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| Dynorphin A (1-17) SCHEMBL29599476 | 0.94 | OPRD1 (0.70) | OPRD1 | |
| Dynorphin A (1-17) SCHEMBL29358748 | 0.94 | OPRD1 (0.70) | OPRD1 | |
| SCHEMBL30658277 | 0.93 | NPY2R (0.75) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30404538 | 0.92 | KEAP1 (0.65) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29461541 | 0.91 | NPY1R (0.70) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30658215 | 0.91 | NPY1R (0.72) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30006939 | 0.91 | KEAP1 (0.70) | NPY1RNPY2RNPY4RNPY5RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | BIOHAVEN THERAPEUTICS LTD. (VG) | 2026-03-03 | — | — | US | disclosed |
| US-20250347677-A1 | BIOLOGICAL NANOPORES HAVING TUNABLE PORE DIAMETERS AND USES THEREOF AS ANALYTICAL TOOLS | UNIV GRONINGEN (NL) | 2025-11-13 | — | — | US | disclosed |
| WO-2025046236-A1 | METHODS FOR NANOPORE-BASED ANALYTE DETECTION | PORTAL BIOTECH LIMITED (GB) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025040657-A1 | SELECTIVE CYCLIZED PEPTIDE KAPPA-OPIOID RECEPTOR ANTAGONISTS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025040658-A1 | SELECTIVE CYCLIZED PEPTIDE KAPPA-OPIOID RECEPTOR AGONISTS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2025-02-27 | — | — | WO | disclosed |
| US-12105079-B2 | Biological nanopores having tunable pore diameters and uses thereof as analytical tools | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-10-01 | — | — | US | disclosed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20230077811-A1 | ACTIVATION OF NEUROPEPTIDE RECEPTORS ON PLASMACYTOID DENDRITIC CELLS TO TREAT OR PREVENT OCULAR DISEASES ASSOCIATED WITH NEOVASCULARIZATION AND INFLAMMATION | TRUSTEES OF TUFTS COLLEGE | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | NPY1R 38/4885NPY2R 37/4885NPY4R 20/4885 |
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | CERS2, CNR2, FAAH2 | NPY1R 249/4885NPY2R 398/4885NPY4R 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.